clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT01696279 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | Hungary | Q28 |
Poland | Q36 | ||
Turkey | Q43 | ||
Germany | Q183 | ||
Romania | Q218 | ||
Chile | Q298 | ||
Argentina | Q414 | ||
P582 | end time | 2018-11-16 | |
P4135 | maximum age | 17 | |
P1050 | medical condition | hyperphosphatemia | Q1641062 |
P2899 | minimum age | 10 | |
P1132 | number of participants | 63 | |
P4844 | research intervention | calcium carbonate | Q23767 |
calcium oxalate | Q412399 | ||
P6153 | research site | Hannover Medical School | Q911561 |
P580 | start time | 2013-03-23 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to <18 Years With Chronic Kidney Disease on Dialysis |